Wall Street analysts expect Ionis Pharmaceuticals Inc (NASDAQ:IONS) to post earnings of ($0.08) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Ionis Pharmaceuticals’ earnings. The highest EPS estimate is $0.29 and the lowest is ($0.50). Ionis Pharmaceuticals posted earnings per share of $0.21 during the same quarter last year, which would indicate a negative year over year growth rate of 138.1%. The business is expected to issue its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that Ionis Pharmaceuticals will report full-year earnings of ($0.14) per share for the current financial year, with EPS estimates ranging from ($0.57) to $0.22. For the next fiscal year, analysts expect that the business will post earnings of $0.35 per share, with EPS estimates ranging from ($1.10) to $2.91. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Ionis Pharmaceuticals.
IONS has been the subject of several research analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. Morgan Stanley boosted their price objective on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 8th. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $50.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $50.76.
In other news, Director Joseph Klein III sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $55.39, for a total transaction of $166,170.00. Following the completion of the transaction, the director now directly owns 7,127 shares of the company’s stock, valued at $394,764.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Elizabeth L. Hougen sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $57.00, for a total value of $228,000.00. Following the transaction, the senior vice president now directly owns 14,392 shares of the company’s stock, valued at $820,344. The disclosure for this sale can be found here. Insiders have sold 133,885 shares of company stock valued at $7,002,841 over the last ninety days. Corporate insiders own 2.13% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Majedie Asset Management Ltd boosted its position in shares of Ionis Pharmaceuticals by 8.8% during the fourth quarter. Majedie Asset Management Ltd now owns 80,696 shares of the company’s stock worth $4,059,000 after buying an additional 6,500 shares during the period. American Century Companies Inc. boosted its position in shares of Ionis Pharmaceuticals by 3.2% during the fourth quarter. American Century Companies Inc. now owns 1,181,109 shares of the company’s stock worth $59,410,000 after buying an additional 36,583 shares during the period. North Star Asset Management Inc. acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $765,000. IFG Advisory LLC acquired a new position in shares of Ionis Pharmaceuticals during the fourth quarter worth approximately $256,000. Finally, Steward Partners Investment Advisory LLC boosted its position in shares of Ionis Pharmaceuticals by 163.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,198 shares of the company’s stock worth $261,000 after buying an additional 3,223 shares during the period. 91.44% of the stock is owned by institutional investors.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.